Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 17,113 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 58
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 53 more

Conditions: Colorectal Neoplasms
Interventions: Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 81
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Springdale, Arkansas + 67 more

Conditions: Health Impairment, Pain, Obesity
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Male only
Enrollment: 3,355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1957 – 2011
U.S. locations: 2
States / cities: Cambridge, Massachusetts • Philadelphia, Pennsylvania

Conditions: Vulvovaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more

Conditions: HIV Infections
Interventions: HIV test by oral swab; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Viral Hepatitis, Hepatitis B Infection
Interventions: Interview, Biospecimen Collection, Electronic Health Record Review; Other · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: High Triglycerides
Interventions: NST-1024, Placebo; Drug · Other
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more

Conditions: Overweight and Obesity
Interventions: Epitomee Capsule, Control-Placebo; Device · Other
Lead sponsor: Epitomee medical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 6 more

Conditions: Phantom Pain Following Amputation of Lower Limb, Amputation
Interventions: Active Virtual Reality Treatment; Behavioral
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Cocaine Dependence
Interventions: Nepicastat, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 7 more

Conditions: Chronic Subdural Hematoma
Interventions: Conventional Surgery, Middle Meningeal Artery Embolization (MMAE); Procedure · Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 40 Years to 90 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 26 more

Conditions: Severe, Symptomatic, Calcific Aortic Stenosis
Interventions: TAVR Implantation with SAPIEN XT, TAVR Implantation with SAPIEN; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 19 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 53
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 45 more

Conditions: Overactive Bladder
Interventions: Oxybutinyn Vaginal Ring 4mg, Oxybutinyn Vaginal Ring 6mg; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 35
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 28 more

Conditions: HIV Infections, AIDS-Related Opportunistic Infections
Interventions: Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 24 more

Conditions: Transient Ischemic Attack, Stroke
Interventions: Aspirin, Clopidogrel, Simvastatin; Drug
Lead sponsor: University of Calgary; Other
Eligibility: 40 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms, Juxtarenal Aneurysms
Interventions: Zenith® Fenestrated AAA Endovascular Graft; Device
Lead sponsor: Cook Group Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: San Francisco, California • Gainesville, Florida • Indianapolis, Indiana + 11 more

Conditions: Amaurosis of Leber, Retinal Diseases
Interventions: rAAV2-CBSB-hRPE65; Genetic
Lead sponsor: University of Pennsylvania; Other
Eligibility: 8 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 2
States / cities: Gainesville, Florida • Philadelphia, Pennsylvania

Conditions: Enteral Nutrition's Effect on the Gut
Interventions: Kate Farms Peptide 1.5, Crohn's disease exclusion diet; Dietary Supplement · Other
Lead sponsor: James Lewis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions: Flortaucipir F18, Brain PET scan; Drug · Procedure
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more

Conditions: Primary Graft Dysfunction, Lung Transplantation
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 13 Years to 68 Years
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Subjects
Interventions: ERB-257, placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: JNJ-89495120, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more

Conditions: Esophagitis, Reflux, Esophagitis, Peptic
Interventions: Dexlansoprazole MR, Lansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 100
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more

Conditions: Diabetes Mellitus, Type 2
Interventions: muraglitazar; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 108
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more

Search by objective public record fields.

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

High School Football and Adult Health

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Rapid HIV Testing Program in the Emergency Department

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity

Efficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg Pain.Home-Based Treatment

A Multi-Center Trial of Nepicastat for Cocaine Dependence

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B

A Safety Extension Study of DR-OXY-301

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

Healthy Volunteers Enteral Nutrition Study (HEN)

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation

Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone